The Accu-Chek Solo micropump system from Roche has gained FDA approval, providing a new insulin delivery solution for individuals aged 2 years and older with type 1 diabetes. The system comprises a tubeless insulin pump and a wireless handheld controller featuring Bluetooth connectivity. Similar to the Omnipod, the Accu-Chek Solo is worn as a patch directly on the body and is controlled wirelessly from a touchscreen handheld device.
The system consists of five total components:
Notable features of the Accu-Chek Solo include a transparent reservoir for air bubble detection, varying cannula lengths, and a "pen-therapy mode" allowing temporary transitions to an insulin pen with no data loss.
There is no smartphone app for controlling the pump or remote monitoring. Also, the system doesn't currently connect with continuous glucose monitors (CGMs), but Roche is exploring CGM integration capabilities in future iterations of the micropump system.
The Accu-Chek Solo enters the US market as the second tubeless insulin pump after Omnipod. No date for US availability has been provided. More to come.
This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or healthcare provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit diabeteseducator.org.
ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any questions.